EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring skeletal muscle tolerance and whole‐body metabolic effects of FDA ‐approved drugs in a volumetric muscle loss model

Shefali R Bijwadia iD, Christiana J Raymond-Pope iD, Alec M Basten iD, Mason T Lentz iD, Thomas J Lillquist iD, Jarrod A Call iD, Sarah M Greising iD

Physiological Reports · 2023

DOI: 10.14814/phy2.15756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Physiological Reports, 2023. Verfasst von Shefali R Bijwadia und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Kinesiology, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Regeneration, Muscular Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Congressionally Directed Medical Research Programs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Volumetric muscle loss (VML) is associated with persistent functional impairment due to a lack of de novo muscle regeneration. As mechanisms driving the lack of regeneration continue to be established, adjunctive pharmaceuticals to address the pathophysiology of the remaining muscle may offer partial remediation. Studies were designed to evaluate the tolerance and efficacy of two FDA‐approved pharmaceutical modalities to address the pathophysiology of the remaining muscle tissue after VML injury: (1) nintedanib (an anti‐fibrotic) and (2) combined formoterol and leucine (myogenic promoters). Tolerance was first established by testing low‐ and high‐dosage effects on uninjured skeletal muscle mass and myofiber cross‐sectional area in adult male C57BL/6J mice. Next, tolerated doses of the two pharmaceutical modalities were tested in VML‐injured adult male C57BL/6J mice after an 8‐week treatment period for their ability to modulate muscle strength and whole‐body metabolism. The most salient findings indicate that formoterol plus leucine mitigated the loss in muscle mass, myofiber number, whole‐body lipid oxidation, and muscle strength, and resulted in a higher whole‐body metabolic rate ( p ≤ 0.016); nintedanib did not exacerbate or correct aspects of the muscle pathophysiology after VML. This supports ongoing optimization efforts, including scale‐up evaluations of formoterol treatment in large animal models of VML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegenerationMuscular DiseasesMiceAnimalsMaleLeucineDisease Models, AnimalMice, Inbred C57BLMuscle, SkeletalPharmaceutical Preparations

Stichwörter der Autor:innen

formoterolmuscle functionneuromusculoskeletal injurynintedanibskeletal muscle injury

Substanzen

LeucinePharmaceutical Preparations

Autor:innen und Institutionen

  • School of Kinesiology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Physiology and Pharmacology, University of Georgia, Athens, Georgia, USA.
  • Regenerative Bioscience Center, University of Georgia, Athens, Georgia, USA.

ORCID-Profile: Shefali R Bijwadia, Christiana J Raymond-Pope, Alec M Basten, Mason T Lentz, Thomas J Lillquist, Jarrod A Call, Sarah M Greising

Förderung

  • Congressionally Directed Medical Research Programs

Zitieren

APA

Bijwadia, S. R., Raymond-Pope, C. J., Basten, A. M., Lentz, M. T., Lillquist, T. J., Call, J. A., & Greising, S. M. (2023). Exploring skeletal muscle tolerance and whole‐body metabolic effects of FDA ‐approved drugs in a volumetric muscle loss model. Physiological Reports. https://doi.org/10.14814/phy2.15756

Vancouver

Bijwadia SR, Raymond-Pope CJ, Basten AM, Lentz MT, Lillquist TJ, Call JA, et al. Exploring skeletal muscle tolerance and whole‐body metabolic effects of FDA ‐approved drugs in a volumetric muscle loss model. Physiological Reports. 2023. doi:10.14814/phy2.15756

BibTeX
@article{Bijwadia2023,
  author = {Bijwadia, Shefali R and Raymond-Pope, Christiana J and Basten, Alec M and Lentz, Mason T and Lillquist, Thomas J and Call, Jarrod A and Greising, Sarah M},
  title = {Exploring skeletal muscle tolerance and whole‐body metabolic effects of FDA ‐approved drugs in a volumetric muscle loss model},
  journal = {Physiological Reports},
  year = {2023},
  doi = {10.14814/phy2.15756}
}
Kostenlos starten →